A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
Sponsored by Bristol-Myers Squibb
About this study
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).
Where this study is enrolling
- Call 303-981-2305
Colorado Blood Cancer Institute
Denver, Colorado
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
Who can participate
Inclusion criteria
- ✓\- Adult participants with rheumatoid arthritis (RA) who meet definition of difficult-to-treat.
Exclusion criteria
- ✕Juvenile arthritis or onset of inflammatory arthritis before age 18.
- ✕Seronegative RA participants in whom polymyalgia rheumatica has not been ruled out.
- ✕Active fibromyalgia with pain symptoms or signs that would interfere with joint assessment.
- ✕Other protocol-defined Inclusion/Exclusion criteria apply.
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.